Literature DB >> 11162627

High expression of HLA-A2 on an oral squamous cell carcinoma with down-regulated transporter for antigen presentation.

M Matsui1, M Ikeda , T Akatsuka.   

Abstract

Using the reverse transcription PCR, we evaluated expression levels of various antigen presentation-related genes, including LMP2, LMP7, MECL-1, PA28alpha, PA28beta, TAP1, TAP2, and tapasin, in two oral squamous cell carcinoma cell lines, HSC5 and HSC7. Expression levels of LMP2, MECL-1, TAP1, and TAP2 transcripts are reduced in both cell lines in comparison with a normal epithelial cell line. Further, HSC5 and HSC7 show diminished expression of LMP7/tapasin, and PA28alpha/beta, respectively. Surface expression of HLA-B alleles is down-regulated in both lines presumably due to low expression of TAP1/2. However, HLA-A2 surface expression is not significantly down-regulated in HSC5 cells, suggesting an involvement of signal-sequence derived peptides in the TAP-independent pathway. The current study would contribute to our understanding of significance of abnormalities in the antigen presentation machinery of oral squamous cell carcinoma, and provide meaningful information in the design of CTL-based tumor vaccines by intra-cellular delivery system. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11162627     DOI: 10.1006/bbrc.2000.4234

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.

Authors:  Joshua D Horton; Hannah M Knochelmann; Terry A Day; Chrystal M Paulos; David M Neskey
Journal:  Trends Cancer       Date:  2019-03-20

Review 2.  Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance.

Authors:  Robert L Ferris; Jennifer L Hunt; Soldano Ferrone
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

3.  Clinical and immunological remarks about TAP deficiency.

Authors:  Jacques Zimmer; Marwan Sleiman; François Hentges; Stephan D Gadola
Journal:  J Biol Chem       Date:  2012-08-03       Impact factor: 5.157

4.  Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen.

Authors:  Nathalie Vigneron; Violette Ferrari; Benoît J Van den Eynde; Peter Cresswell; Ralf M Leonhardt
Journal:  J Immunol       Date:  2018-08-22       Impact factor: 5.422

5.  Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes.

Authors:  Michael S Leibowitz; Pedro A Andrade Filho; Soldano Ferrone; Robert L Ferris
Journal:  Cancer Immunol Immunother       Date:  2011-01-05       Impact factor: 6.968

Review 6.  Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.

Authors:  Jennifer D Moy; Jessica M Moskovitz; Robert L Ferris
Journal:  Eur J Cancer       Date:  2017-03-18       Impact factor: 9.162

7.  SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells.

Authors:  Michael S Leibowitz; Raghvendra M Srivastava; Pedro A Andrade Filho; Ann Marie Egloff; Lin Wang; Raja R Seethala; Soldano Ferrone; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2013-01-30       Impact factor: 12.531

Review 8.  Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes.

Authors:  Thomas Duhen; Michael J Gough; Rom S Leidner; Sasha E Stanton
Journal:  Front Oral Health       Date:  2022-07-22

9.  Polymorphisms of Antigen-Presenting Machinery Genes in Non-Small Cell Lung Cancer: Different Impact on Disease Risk and Clinical Parameters in Smokers and Never-Smokers.

Authors:  Andrzej Wiśniewski; Maciej Sobczyński; Konrad Pawełczyk; Irena Porębska; Monika Jasek; Marta Wagner; Wanda Niepiekło-Miniewska; Aneta Kowal; Joanna Dubis; Natalia Jędruchniewicz; Piotr Kuśnierczyk
Journal:  Front Immunol       Date:  2021-05-31       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.